Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Merimepodib · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Merimepodib | DRUG | - |
| PEG-Interferon-alpha 2a (Pegasys®) | DRUG | - |
| Ribavirin (Copegus®) | DRUG | - |
Inclusion Criteria: The following is a summary of the inclusion and exclusion criteria for the Merimepodib Triple Combination (METRO) trial. There are also additional criteria, which will be reviewed with you by the staff at the clinical study site, to make sure you are eligible for the study. Some...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
Merimepodib is an investigational small molecule being studied for the treatment of Hepatitis C, a viral infection of the liver. It is being developed by Vertex Pharmaceuticals Incorporated (VRTX) and has completed a Phase 2 clinical trial in patients with chronic Hepatitis C.
Merimepodib is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. The company conducted a Phase 2 clinical trial of the drug for the treatment of chronic Hepatitis C.
Merimepodib is in Phase 2 clinical development. It has completed a Phase 2 trial for the treatment of chronic Hepatitis C, but it is not approved and remains an investigational drug. The completed trial enrolled 315 participants and was randomized and double-blind.
Merimepodib has one completed clinical trial, registered as NCT00088504, titled "Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C." This Phase 2 study enrolled 315 participants in the United States and evaluated the drug in patients with Hepatitis C.
Merimepodib is a small molecule that inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in the synthesis of guanine nucleotides. By blocking this enzyme, the drug reduces the availability of nucleotides needed for viral RNA replication, thereby inhibiting the replication of the Hepatitis C virus.